[
  {
    "ts": null,
    "headline": "Top Stock Reports for JPMorgan Chase, Chevron & Shopify",
    "summary": "JPMorgan Chase posts 43.9% annual gain, fueled by loan demand and high rates, but faces expense growth and asset quality concerns.",
    "url": "https://finnhub.io/api/news?id=35a181a3337b952e50086bf36d7554ec35e30d93bdda802b2e7d632e9698cd74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754685480,
      "headline": "Top Stock Reports for JPMorgan Chase, Chevron & Shopify",
      "id": 136276197,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "JPMorgan Chase posts 43.9% annual gain, fueled by loan demand and high rates, but faces expense growth and asset quality concerns.",
      "url": "https://finnhub.io/api/news?id=35a181a3337b952e50086bf36d7554ec35e30d93bdda802b2e7d632e9698cd74"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Reports 16 Deaths Linked To Defibrillator Lead Issue",
    "summary": "The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE:BSX) ENDOTAK RELIANCE defibrillation leads, following a letter from the company alerting healthcare providers of possible reduced shock efficacy. Boston Scientific’s ENDOTAK RELIANCE leads are used with implantable cardioverter-defibrillators (ICDs) to deliver pacing and shock therapy to prevent sudden cardiac death. The affected leads are coated with",
    "url": "https://finnhub.io/api/news?id=183dc77a130049ab32fd35ace2d7d73cfd617b580babef1a7f2b580980a3103e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754670248,
      "headline": "Boston Scientific Reports 16 Deaths Linked To Defibrillator Lead Issue",
      "id": 136276394,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE:BSX) ENDOTAK RELIANCE defibrillation leads, following a letter from the company alerting healthcare providers of possible reduced shock efficacy. Boston Scientific’s ENDOTAK RELIANCE leads are used with implantable cardioverter-defibrillators (ICDs) to deliver pacing and shock therapy to prevent sudden cardiac death. The affected leads are coated with",
      "url": "https://finnhub.io/api/news?id=183dc77a130049ab32fd35ace2d7d73cfd617b580babef1a7f2b580980a3103e"
    }
  },
  {
    "ts": null,
    "headline": "Inogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/Y",
    "summary": "INGN stock rises as Q2 loss narrows and revenue climbs 4% year over year, driven by strong B2B demand despite DTC and rental declines.",
    "url": "https://finnhub.io/api/news?id=7411e6382fa9a89de20da82ec103383345153875770d700b741309c562f0d478",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754669460,
      "headline": "Inogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/Y",
      "id": 136276395,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "INGN stock rises as Q2 loss narrows and revenue climbs 4% year over year, driven by strong B2B demand despite DTC and rental declines.",
      "url": "https://finnhub.io/api/news?id=7411e6382fa9a89de20da82ec103383345153875770d700b741309c562f0d478"
    }
  },
  {
    "ts": null,
    "headline": "PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises",
    "summary": "PACB stock jumps after Q2 results beat estimates, with narrow losses, rising margins, and strong global demand.",
    "url": "https://finnhub.io/api/news?id=3160669a42864fd46cf78a720f5ae2d4fecba645a3e9082e93da750b1f9a72b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754669220,
      "headline": "PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises",
      "id": 136276396,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "PACB stock jumps after Q2 results beat estimates, with narrow losses, rising margins, and strong global demand.",
      "url": "https://finnhub.io/api/news?id=3160669a42864fd46cf78a720f5ae2d4fecba645a3e9082e93da750b1f9a72b9"
    }
  },
  {
    "ts": null,
    "headline": "DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down",
    "summary": "Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.",
    "url": "https://finnhub.io/api/news?id=b94dcc7b9ad97858599a7f02ff56d929a483dcb100c40cbdc9fb5aa28be78945",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754668260,
      "headline": "DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down",
      "id": 136276397,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.",
      "url": "https://finnhub.io/api/news?id=b94dcc7b9ad97858599a7f02ff56d929a483dcb100c40cbdc9fb5aa28be78945"
    }
  },
  {
    "ts": null,
    "headline": "AMN Stock Slips Despite Q2 Earnings & Revenue Beat, Margins Down",
    "summary": "AMN Healthcare tops second-quarter 2025 earnings and revenue forecasts, but margins and segment sales face continued pressure.",
    "url": "https://finnhub.io/api/news?id=ff6f3546e9d211aaab270804420a809de8595e69e6e1f208e5d77c85e6e44bae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754668020,
      "headline": "AMN Stock Slips Despite Q2 Earnings & Revenue Beat, Margins Down",
      "id": 136276398,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "AMN Healthcare tops second-quarter 2025 earnings and revenue forecasts, but margins and segment sales face continued pressure.",
      "url": "https://finnhub.io/api/news?id=ff6f3546e9d211aaab270804420a809de8595e69e6e1f208e5d77c85e6e44bae"
    }
  },
  {
    "ts": null,
    "headline": "Solventum Stock Gains on Q2 Earnings & Revenue Beat, Margins Improve",
    "summary": "SOLV jumps 5% as Q2 earnings and revenues beat estimates; EPS outlook raised on broad-based segment growth.",
    "url": "https://finnhub.io/api/news?id=b745202d58a017ac2461710e696dc864bb982ce563c47cb7ab7b89e5a3495ee1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754660700,
      "headline": "Solventum Stock Gains on Q2 Earnings & Revenue Beat, Margins Improve",
      "id": 136267973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "SOLV jumps 5% as Q2 earnings and revenues beat estimates; EPS outlook raised on broad-based segment growth.",
      "url": "https://finnhub.io/api/news?id=b745202d58a017ac2461710e696dc864bb982ce563c47cb7ab7b89e5a3495ee1"
    }
  },
  {
    "ts": null,
    "headline": "Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock",
    "summary": "Abbott outpaces market trends as EPD sales surge, fueled by double-digit growth, biosimilar approvals and strong product demand.",
    "url": "https://finnhub.io/api/news?id=81404eea55a3f2d53c7745ab8cf969aa59f2226e14b2dbfb461cb088f20d4d08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754660340,
      "headline": "Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock",
      "id": 136273688,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Abbott outpaces market trends as EPD sales surge, fueled by double-digit growth, biosimilar approvals and strong product demand.",
      "url": "https://finnhub.io/api/news?id=81404eea55a3f2d53c7745ab8cf969aa59f2226e14b2dbfb461cb088f20d4d08"
    }
  },
  {
    "ts": null,
    "headline": "Tariffs Be Damned. Stocks Flirt With a New Record High.",
    "summary": "Tariffs Be Damned. Stocks Flirt With a New Record High.",
    "url": "https://finnhub.io/api/news?id=605a210f5f4851711d50b836243607b7cde31069c371bcc16fed56f77cced7cf",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754659020,
      "headline": "Tariffs Be Damned. Stocks Flirt With a New Record High.",
      "id": 136296160,
      "image": "",
      "related": "BSX",
      "source": "MarketWatch",
      "summary": "Tariffs Be Damned. Stocks Flirt With a New Record High.",
      "url": "https://finnhub.io/api/news?id=605a210f5f4851711d50b836243607b7cde31069c371bcc16fed56f77cced7cf"
    }
  },
  {
    "ts": null,
    "headline": "TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market",
    "summary": "Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product launches.",
    "url": "https://finnhub.io/api/news?id=102b09ff4c2c6dc3b60fad553e3ffe38b30da132a8082355d751f74e5bfcdea7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754657220,
      "headline": "TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market",
      "id": 136266887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product launches.",
      "url": "https://finnhub.io/api/news?id=102b09ff4c2c6dc3b60fad553e3ffe38b30da132a8082355d751f74e5bfcdea7"
    }
  },
  {
    "ts": null,
    "headline": "Disposable Endoscopes Market Insights, Competitive Landscape, and Market Forecast 2024-2032 | Olympus, Boston Scientific, and Ambu Drive Market Innovation with Innovative Product Launches",
    "summary": "The disposable endoscopes market, segmented by product, application, end-user, and geography, is projected to expand significantly, reaching USD 5.74 billion by 2032 from USD 2.65 billion in 2024. Driven by rising healthcare-associated infections, chronic diseases, and technological advancements, North America is set to dominate this growth.Dublin, Aug. 08, 2025 (GLOBE NEWSWIRE) -- The \"Disposable Endoscopes - Market Insights, Competitive Landscape, and Market Forecast - 2032\" has been added to",
    "url": "https://finnhub.io/api/news?id=2b96cdb121bcff80d8b1f9bd4453661705c1117e4c192dfce41b85c20001bf80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754649600,
      "headline": "Disposable Endoscopes Market Insights, Competitive Landscape, and Market Forecast 2024-2032 | Olympus, Boston Scientific, and Ambu Drive Market Innovation with Innovative Product Launches",
      "id": 136266888,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The disposable endoscopes market, segmented by product, application, end-user, and geography, is projected to expand significantly, reaching USD 5.74 billion by 2032 from USD 2.65 billion in 2024. Driven by rising healthcare-associated infections, chronic diseases, and technological advancements, North America is set to dominate this growth.Dublin, Aug. 08, 2025 (GLOBE NEWSWIRE) -- The \"Disposable Endoscopes - Market Insights, Competitive Landscape, and Market Forecast - 2032\" has been added to",
      "url": "https://finnhub.io/api/news?id=2b96cdb121bcff80d8b1f9bd4453661705c1117e4c192dfce41b85c20001bf80"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific updates instructions of devices linked to 17 deaths",
    "summary": "The update covers devices used in procedures to implant the company’s Watchman heart device.",
    "url": "https://finnhub.io/api/news?id=4bdfab7a3de23b731aa9f213758456303fa4f69ce3626194086a9804d6d8d7c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754635683,
      "headline": "Boston Scientific updates instructions of devices linked to 17 deaths",
      "id": 136276401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The update covers devices used in procedures to implant the company’s Watchman heart device.",
      "url": "https://finnhub.io/api/news?id=4bdfab7a3de23b731aa9f213758456303fa4f69ce3626194086a9804d6d8d7c5"
    }
  },
  {
    "ts": null,
    "headline": "Q2 Medical Devices & Supplies - Diversified Earnings: Boston Scientific (NYSE:BSX) Earns Top Marks",
    "summary": "The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Boston Scientific (NYSE:BSX) and the rest of the medical devices & supplies - diversified stocks fared in Q2.",
    "url": "https://finnhub.io/api/news?id=44dc0cbf8e793dad85df07c0394e49a8edee46d7238125c2279477dbf16ad0b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754623872,
      "headline": "Q2 Medical Devices & Supplies - Diversified Earnings: Boston Scientific (NYSE:BSX) Earns Top Marks",
      "id": 136266889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Boston Scientific (NYSE:BSX) and the rest of the medical devices & supplies - diversified stocks fared in Q2.",
      "url": "https://finnhub.io/api/news?id=44dc0cbf8e793dad85df07c0394e49a8edee46d7238125c2279477dbf16ad0b6"
    }
  }
]